Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
AssigneeBiogen Idec MA Inc.
InventorPaul Rennert
Life of this patent
Estimating the term…
Abstract
The present invention relates to reagents which modify the activity of TWEAK and their use as therapeutic agents for the treatment of immunological disorders.
Claims68
A method for blocking the development or treating or reducing the severity or effects of an immunological disorder in an animal comprising the step of administering a pharmaceutical composition which comprises a therapeutically effective amount of a TWEAK blocking agent and a pharmaceutically acceptable carrier.
A method for inhibiting an immune response in an animal comprising the step of administering a pharmaceutical composition which comprises an effective amount of a TWEAK blocking agent and a pharmaceutically effective carrier.
A pharmaceutical composition comprising a therapeutically effective amount of a TWEAK blocking agent and a pharmaceutically acceptable carrier.
A method of treating a Th1 mediated disorder in a mammal comprising administering to said mammal an effective amount of an antagonist molecule, wherein said antagonist is selected from the group consisting of
- a) an anti-TWEAK antibody;
- b) an anti-TWEAK receptor antibody;
- c) a fusion protein comprising the extracellular domain of TWEAK receptor and all or part of an immunoglobulin;
- d) an agent or molecule which blocks or interrupts intracellular signaling of TWEAK receptor.
A method of treating a Th2 mediated disorder in a mammal comprising administering to said mammal an effective amount of an antagonist molecule, wherein said antagonist is selected from the group consisting of
- a) an anti-TWEAK antibody;
- b) an anti-TWEAK receptor antibody;
- c) a fusion protein comprising the extracellular domain of TWEAK receptor and all or part of an immunoglobulin;
- d) an agent or molecule which blocks or interrupts intracellular signaling of TWEAK receptor.
A method for blocking the development or treating or reducing the severity or effects of an immunological disorder in an animal comprising the step of administering a therapeutically effective amount of an antibody that binds to a TWEAK polypeptide consisting of SEQ ID NO:1 or SEQ ID NO:2, wherein the immunological disorder is rheumatoid arthritis or inflammatory bowel disease.
A monoclonal antibody that specifically recognizes the epitope to which monoclonal antibody AB.D3, produced by the hybridoma having ATCC Accession No. HB-12622, specifically binds.
Dependencies are inferred from the claim text.